The use of intravenous bisphosphonate therapy to treat vertebral fractures due to osteoporosis among boys with Duchenne muscular dystrophy.
about
Interventions to prevent steroid-induced osteoporosis and osteoporotic fractures in Duchenne muscular dystrophyCurrent and emerging treatment strategies for Duchenne muscular dystrophyRare causes of osteoporosisBisphosphonate therapy in pediatric patientsThe management of osteoporosis in children.Bisphosphonate treatment for children with disabling conditions.A practical guide to the monitoring and management of the complications of systemic corticosteroid therapyImpaired bone homeostasis in amyotrophic lateral sclerosis mice with muscle atrophy.An update on childhood bone health: mineral accrual, assessment and treatment.Short-Term Safety of Zoledronic Acid in Young Patients With Bone Disorders: An Extensive Institutional Experience.Feasibility and tolerability of whole-body, low-intensity vibration and its effects on muscle function and bone in patients with dystrophinopathies: a pilot study.Optimizing Bone Health in Duchenne Muscular Dystrophy.Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy.Bisphosphonate Withdrawal: Effects on Bone Formation and Bone Resorption in Maturing Male Mice.Osteoporosis in Children with Chronic Illnesses: Diagnosis, Monitoring, and Treatment.The time to and determinants of first fractures in boys with Duchenne muscular dystrophy.Histomorphometry and Bone Matrix Mineralization Before and After Bisphosphonate Treatment in Boys With Duchenne Muscular Dystrophy: A Paired Transiliac Biopsy Study.Zoledronic acid in pediatric metabolic bone disorders.Therapeutic Options to Improve Bone Health Outcomes in Duchenne Muscular Dystrophy: Zoledronic Acid and Pubertal Induction.Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management.[Current care strategies for Duchenne muscular dystrophy].Prophylactic oral bisphosphonate therapy in duchenne muscular dystrophy.Bone health in facioscapulohumeral muscular dystrophy: A cross-sectional study.
P2860
Q24198280-0AC172C9-B83D-4684-AF47-B23F26713F13Q26741535-AC5AFC9D-69C8-4AD0-B821-F758F2D64FA2Q26775750-F470A51E-7900-4FB6-84E0-DF46FF1EA700Q26830702-F943B4D9-7451-46E8-97F6-0C5873CF35ABQ30251490-6BEB71DA-A0AB-4E40-9C08-41108305ED25Q33680621-4107E82F-9E0C-4D5C-891E-462821D6E146Q34364143-CFE05CC0-3DB2-4655-9CEE-317F1D436C9CQ35221512-ABB13154-AE2D-4BFF-AF8B-C812A1358E8CQ35510163-66618930-CA79-4BD5-B254-8F3EAA9DF6D8Q36433566-31010797-2C12-4F08-8161-054A15A792CFQ37742574-AA862612-B115-420D-99AA-73FD7FBCA92CQ38540530-AC211286-A7DE-4A81-9A0D-D0086EAAFF26Q38766431-D30128EF-59E5-407F-89D3-2744E8184F28Q39124555-64FEAACE-8E2A-45E4-9A29-C287FC3250EBQ39377609-B933988C-0107-48AA-A1A5-A01A1C9A7FB5Q40520731-DF39FC16-6DA6-45D1-B2B0-6D05500E35C3Q41090739-12BA72C6-F1B5-48BF-9D3A-D54EC2766B3CQ47139370-D796061B-4D46-408C-80B0-4367437179F7Q50072940-02B71252-BEA8-420F-B116-E8A72715DCF1Q50207377-C84CC5CD-AFD9-4839-B36D-D6DE3D2C03ACQ50657212-9F29D9FC-78C3-4D6E-8870-1DDDFF22FCE5Q51294715-AE609759-DD39-48FA-87CA-FFF3F685B31AQ53495823-CB8643CF-4B0F-4634-9208-EF05F6E85F92
P2860
The use of intravenous bisphosphonate therapy to treat vertebral fractures due to osteoporosis among boys with Duchenne muscular dystrophy.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
The use of intravenous bisphos ...... h Duchenne muscular dystrophy.
@en
type
label
The use of intravenous bisphos ...... h Duchenne muscular dystrophy.
@en
prefLabel
The use of intravenous bisphos ...... h Duchenne muscular dystrophy.
@en
P2093
P2860
P1476
The use of intravenous bisphos ...... h Duchenne muscular dystrophy.
@en
P2093
A M Sbrocchi
A McCormick
H J McMillan
M A Matzinger
P2860
P2888
P304
P356
10.1007/S00198-012-1911-3
P407
P50
P577
2012-11-01T00:00:00Z
P5875
P6179
1033385764